Jaime Soto, MD; Julia Toledo, MD; Maria Rodriquez, Med Tech; Jorge Sanchez, Med Tech; Ricardo Herrera, MD; Julio Padilla, MD; Jonathan Berman, MD, PhD
Primaquine had a prophylactic efficacy of 90% to 95% against infection with Plasmodium falciparum and P. vivax in Indonesian settlers.
To evaluate the efficacy of primaquine prophylaxis for protecting nonimmune persons from malaria.
Randomized, double-blind, placebo-controlled field study.
A malaria-endemic area in Colombia.
176 healthy, young, nonimmune adult male soldiers.
Primaquine, 30 mg/d, or matching placebo during 15 weeks of patrol in the endemic area and 1 week afterward.
Symptomatic parasitemia was determined over the 16-week intervention period and for 3 weeks in base camp.
Protective efficacy in the primaquine group (122 participants) was 89% (95% CI, 75% to 96%) against all types of malaria, 94% (CI, 78% to 99%) against P. falciparum malaria, and 85% (CI, 57% to 95%) against P. vivax malaria. Six primaquine recipients had mild to moderate gastrointestinal distress, and three had severe distress.
For prophylaxis against P. falciparum malaria, primaquine has an efficacy and toxicity competitive with those of standard agents. A potential advantage of primaquine is that prophylaxis may be discontinued 1 week after the recipient has left the endemic area.
Soto J, Toledo J, Rodriquez M, et al. Primaquine Prophylaxis against Malaria in Nonimmune Colombian Soldiers: Efficacy and Toxicity: A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 1998;129:241–244. doi: 10.7326/0003-4819-129-3-199808010-00013
Download citation file:
Published: Ann Intern Med. 1998;129(3):241-244.
Emergency Medicine, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use